New pill RAP-103 aims to clear psoriasis in 8 weeks
Disease control
Recruiting now
This Phase 2 trial tests whether the oral drug RAP-103 can improve skin clearance and quality of life in people with moderate to severe psoriasis. About 90 adults aged 18 to 70 will take either a daily or twice-daily dose of RAP-103 or a placebo for 8 weeks. The study measures ho…
Phase: PHASE2 • Sponsor: Clarent Biopharma, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC